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A B S T R A C T   
Background: Low vitamin D levels, tobacco use and high body mass index (BMI) have been linked to adverse 
disease outcomes in multiple sclerosis (MS), but their influence on long-term disability progression remains 
unclear. Therefore, we explored whether these modifiable lifestyle factors were associated with 10-year clinical 
disability progression in patients with MS. 
Methods: In this prospective study, a cohort of 88 patients with relapsing-remitting MS completed a randomized 
controlled study on ω-3 fatty acids between 2004 and 2008. During 24 months, serum 25-hydroxyvitamin D (25 
(OH)D), serum cotinine (nicotine metabolite), and BMI were repeatedly measured. In 2017, a follow-up study 
was conducted among 80 of the participants, including disability assessment by the Expanded Disability Status 
Scale (EDSS). Linear regression was used to explore associations between the lifestyle factors and the EDSS 
change over 10 years. 
Results: Higher seasonally adjusted 25(OH)D levels were associated with lower 10-year EDSS progression (change 
in EDSS per 1 SD increase in 25(OH)D in a model adjusted for sex, age and baseline EDSS: -0.45 point, 95% CI: 
-0.75 to -0.16, p=0.003). Further adjustments for potential confounders related to lifestyle and disease status 
gave similar results. The association was mainly driven by low 25(OH)D levels during spring, as well as 
seasonally adjusted levels below 80 nmol/L. No clear association was found for BMI and cotinine. 
Conclusion: Lower 25(OH)D levels, but apparently not tobacco use or higher BMI, were significantly associated 
with worse long-term disability progression in MS.   
Abbreviations: DMT, disease-modifying treatment; 25(OH)D, 25-hydroxyvitamin D; RCT, randomized controlled trial; IFN-β, interferon beta 1a; aHSCT, autol-
ogous hematopoietic stem cell transplantation; CUA, combined unique activity. 
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1. Introduction 
Multiple sclerosis (MS) is a disabling chronic disease with several 
disease-modifying treatment (DMT) options, but so far, no curable 
treatment exists (Dobson and Giovannoni, 2019). Established risk factors 
related to lifestyle such as vitamin D deficiency, tobacco smoking, and 
obesity may also affect disease course (Waubant et al., 2019). Higher 
serum levels of 25-hydroxyvitamin D (25(OH)D) have been associated 
with less radiological inflammatory activity and lower relapse rate in 
observational studies (Smolders et al., 2019). However, two larger ran-
domized controlled trials (RCTs) on high dose vitamin D supplementation 
failed to demonstrate a clear effect on relapse rate and disability pro-
gression in the intention-to-treat population (Hupperts et al., 2019, Camu 
et al., 2019). Further, several (Hernan et al., 2005, Healy et al., 2009, 
Manouchehrinia et al., 2013), but not all (Koch et al., 2007, Kvistad et al., 
2016, Munger et al., 2015) studies, suggest that smoking increases the risk 
of a faster disease progression and earlier transition to secondary pro-
gressive MS (SPMS). For obesity, some studies indicate that higher body 
mass index (BMI) leads to more disease activity through weaker therapy 
response (Kvistad et al., 2015, Huppke et al., 2019), and may affect brain 
volume loss (Mowry et al., 2018), whereas other studies have failed to 
demonstrate any association between BMI and disease progression 
(Pilutti et al., 2012, Bove et al., 2016). 
Only a few studies have examined associations between lifestyle 
factors and long-term disability progression in MS (Cortese et al., 2020, 
University of California, San Francisco MS-EPIC Team, 2016). To 
address this, we conducted a study to examine whether 25(OH)D levels, 
tobacco use, and BMI were associated with disability progression over 
10 years, using prospective data from a well-defined Norwegian cohort 
of patients with MS. 
2. Methods 
2.1. Study population and design 
2.1.1. The OFAMS baseline study 
A total of 92 patients with relapsing-remitting MS (RRMS) aged 18- 
55 years were enrolled in an RCT on marine ω-3 fatty acids versus pla-
cebo (the OFAMS study) between 2004 and 2006, and then closely 
followed for 24 months. A detailed description of the study is reported 
elsewhere (Torkildsen et al., 2012). In the following text, we will refer to 
this study as “the baseline study”. Frequent clinical examinations, blood 
samples and MRI scans of the brain were performed during the study 
period. No particular advice on lifestyle changes or vitamin D supple-
mentation was given to the patients. Overall, the study demonstrated no 
significant effect of ω-3 fatty acids on disease activity (Torkildsen et al., 
2012). However, in subsequent analyses, lower 25(OH)D levels were 
associated with more inflammatory MRI-activity before initiation of 
subcutaneous interferon beta 1a (IFN-β) at study month 6 (Loke-
n-Amsrud et al., 2012), and higher BMI was associated with more dis-
ease activity after initiation of IFN-β (Kvistad et al., 2015). 
2.1.2. The OFAMS follow up study 
In 2017, the OFAMS population was invited to a 10-year follow-up 
study to evaluate disease progression and current disability status. A 
trained neurologist at each participating centre performed a clinical 
examination of the patients. In addition, the patients answered a ques-
tionnaire regarding lifestyle habits, including sun exposure and tobacco 
use (smoking and/or snuff use) during the last 10 years. 
2.2. Ethical approvals and Patient Consents 
The OFAMS baseline study and the OFAMS follow-up study were 
approved by the Regional Committee for Medical and Health Research 
Ethics in Western Norway. All participants gave their written informed 
consent prior to the studies. 
2.3. Assessment of lifestyle factors in OFAMS baseline study 
2.3.1. Vitamin D measurement 
Serum samples were collected at the baseline visit, and then at month 
1, 3, 6, 7, 9, 12, 18, and 24. The samples were stored at -80◦C until 
simultaneous analysis of all nine samples from each patient at the 
Department of Medical Biochemistry, St. Olav’s University hospital, 
Trondheim, Norway (Loken-Amsrud et al., 2012). 25(OH)D levels in 
nmol/L were measured by radioimmunoassay (RIA kit; ImmunoDiag-
nostic Systems, Boldon, UK). The coefficient of variation was 5.4% at 29 
nmol/l and 6.3% at 112 nmol/l. 
2.3.2. Cotinine measurement 
Cotinine levels, a sensitive and specific biomarker for nicotine intake 
(SRNT Subcommittee on Biochemical Verification, 2002), were 
measured simultaneously in serum samples collected at baseline visit, 
month 6, 12, 18, and 24 (Kvistad et al., 2016). The analysis was per-
formed by liquid chromatography-tandem mass spectrometry (Bevital 
AS, Bergen, Norway). The within-day coefficient of variation was 2.0% 
to 6.6%, and the between-day coefficient of variation was 3.9%. The 
cut-off value for recent tobacco use was set to cotinine levels > 85 
nmol/L, with tobacco users defined as having > 85 nmol/L in ≥ 60% of 
the samples. 
2.3.3. Body mass index 
The participants’ height (in meters) and weight (in kg) were 
measured at screening, and then at baseline visit, month 1, 3, 6, 7, 9, 12, 
18, and 24. From these values, BMI at each visit was calculated as kg/ 
m2. 
2.4. Other relevant covariates 
Current use of DMT at follow-up was categorized as “none”, “less 
potent” (IFN-β, glatiramer acetate, teriflunomide, and dimethyl fuma-
rate) and “potent” (fingolimod, natalizumab, autologous hematopoietic 
stem cell transplantation (aHSCT), and rituximab). For disease activity, 
we included two variables from the baseline study: the cumulative 
number of combined unique activity (CUA) lesions (Torkildsen et al., 
2012) on subsequent MRI brain scans, and the annual relapse rate. 
At the follow-up visit, the participants were asked about the fre-
quency of outdoor activity in summer season (April-September) 10 years 
ago, 5 years ago and last year, categorizing this into “< 1 time per 
week”, “1-2 times per week”, “3-4 times per week” and “approximately 
daily”. From these data, we created a cumulative sun exposure variable. 
2.5. Outcome measure 
2.5.1. EDSS progression 
The disability status was assessed by the Expanded Disability Status 
Scale (EDSS) (Kurtzke, 1983) at baseline visit, month 6, 12, 18, and 24 
during the baseline study and repeated once in the follow-up study 10 
years later. The EDSS progression was defined as the EDSS change from 
the last score in the baseline study until the score at follow-up. For all 
patients but two the last EDSS score was at month 24; one patient had 
the last score at month 12 and the other one at month 18. 
2.6. Missing values 
92 patients were screened to participate in the baseline study, but 
four were lost to follow-up during the first six months of the study. In the 
follow-up study, 85 of the 91 patients still alive (93.4%) gave their 
consent to participate, including 81 of the 88 patients who completed at 
least 12 months of the baseline study. However, EDSS score at follow-up 
was missing for one of these 81 patients, leaving 80 patients eligible for 
the main analyses. 
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2.7. Statistical analyses 
For each lifestyle factor, we estimated the mean value per patient 
based on all available measurements during the baseline study. Since 
vitamin D levels vary with season in Norway, the 25(OH)D levels were 
seasonally adjusted by a sine function modelled within the baseline 
study, as previously described (Saltyte Benth et al., 2012). 
We used linear regression models to estimate the association be-
tween the lifestyle factors and the EDSS progression from the last score 
in the OFAMS baseline study to the assessment in the follow-up study. 
All exposures were modelled as both categorical (quartiles) and 
continuous variables to maximize power and to explore possible 
nonlinear associations. In continuous analyses, we standardized the 
variables (mean = 0, standard deviation (SD) = 1) to estimate the 
change in EDSS per 1 SD increase in the exposure variable. To test for a 
linear trend across the quartiles, the median value of each quartile was 
included in the regression model as a continuous variable. All available 
measurements in the OFAMS baseline study were used to standardize 
and categorize variables. All models were adjusted for sex, age and 
baseline EDSS score (= last score in the baseline study). In multivariable 
models, we mutually adjusted for all three lifestyle factors, disease ac-
tivity (CUA and annual relapse rate) in the baseline study, disease 
duration (from year of diagnosis until follow-up), and use of DMT at 
follow-up. We also adjusted for cumulative sun exposure in the follow- 
up period, but as this only had a minor influence on the effect esti-
mates, we omitted this variable in the final models. 
To illustrate the monthly fluctuations of 25(OH)D levels in our pop-
ulation, a Locally Estimated Scatterplot Smoothing (LOESS) curve was 
fitted to the available measures, with corresponding 95% confidence in-
tervals (CI). To evaluate whether an association between 25(OH)D levels 
and EDSS progression varied by season, we computed a dichotomized 
variable of < median and ≥ median 25(OH)D levels per season based on 
each patient’s mean 25(OH)D level for that season. The four seasons were 
summer (June-August), fall (September-November), winter (December- 
February), and spring (March-May). We then included the dichotomized 
seasonal variables (< median or ≥ median) as independent variables in 
linear regression analyses, with the change in EDSS score as the depen-
dent variable, adjusted for sex, age and baseline EDSS score. Finally, to 
investigate whether there was a nonlinear relationship between season-
ally adjusted 25(OH)D levels and disease progression, we plotted a 
LOESS-curve to the available data. 
All the statistical analyses were performed in IBM SPSS Statistics, 
version 25.0 (SPSS Inc., Chicago, Ill., USA). The plots were made in R 
version 3.6.0 (The R Foundation) using the ggplot2 package. P-values 
were considered significant at values <0.05. All tests were two-sided. 
3. Results 
3.1. Patient characteristics 
The study population comprised 80 participants who completed 
more than 12 months in the baseline study and had an available EDSS 
score in the follow-up study. Table 1 gives the main baseline charac-
teristics of this population. The mean EDSS score increased from 1.9 (SD: 
0.84) at the baseline visit to 2.8 (SD: 1.6) at the follow-up visit, and 
seven (8.8%) of the patients converted to SPMS during the follow-up 
period. At follow-up, 72.5% received any kind of DMT, including 
seven patients still on IFN-β and two patients on past aHSCT treatment. 
Fewer used tobacco (40.0% vs. 61.3% in the baseline study), and 76.3% 
used vitamin D containing supplements in various doses and formulas. 
For most patients, BMI remained stable over the years, with mean BMI 
25.6 kg/m2 (SD: 4.2) and 25.7 kg/m2 (SD: 4.6) during the baseline and 
follow-up study, respectively. 
3.2. Vitamin D 
Higher 25(OH)D levels were significantly associated with lower 10- 
year EDSS progression (Table 2). In the continuous model adjusted for 
sex, age and baseline EDSS score, 1 SD increase in seasonally adjusted 
average 25(OH)D levels was associated with 0.45 point (95% CI: 0.16- 
0.75, p=0.003) lower progression in EDSS scores at follow-up. Further 
adjustment for other covariates, including mean cotinine levels, mean 
BMI values and disease activity during the baseline study, did not in-
fluence the results. In the categorical analyses, there was a significant 
dose-response relationship between 25(OH)D and change in EDSS score 
with a p-trend of 0.024 in the simplest model (Table 2). The effect es-
timates and the p-trend remained similar when more covariates were 
added to the model. 
Fig. 1 illustrates the seasonal fluctuation of repeated measures of 25 
(OH)D throughout the baseline study, with the highest levels seen in 
August and the lowest levels seen in March. In the model that included 
dichotomized 25(OH)D variables for all four seasons, only higher 
(≥ median) 25(OH)D levels during the spring, when the levels were 
lowest, were significantly associated with 10-year EDSS progression 
(Fig. 2). 
When exploring the possible nonlinear relationship between 25(OH)D 
and disease progression with a LOESS-curve (Fig. 3), an increase in 
seasonally adjusted 25(OH)D levels from around 50-60 nmol/L to 80 nmol/ 
L was associated with approximately one point decrease in EDSS progres-
sion, whereas little additional benefit was seen for higher 25(OH)D levels. 
3.3. Cotinine levels 
Tobacco use based on cotinine levels showed no significant associ-
ation with EDSS progression, neither in the simple model adjusted for 
sex, age, and baseline EDSS score, nor in the models adjusted for addi-
tional variables (Table 2). Although five of seven patients (71%) who 
converted to SPMS were classified as tobacco users during the baseline 
study, this finding was not significant (p= 0.70) according to Fisher’s 
exact two-sided test for small samples. 
3.4. BMI 
For BMI, there was a tendency towards a beneficial effect for the 
patients with BMI values in the highest quartile, but no significant dose- 
response curve was present (Table 2). We found a similar non-significant 
trend in the continuous model. 
4. Discussion 
In this prospective study, we found a significant and consistent as-
sociation between higher 25(OH)D levels and lower 10-year disability 
progression independent of potential confounders related to lifestyle 
Table 1 
Characteristics of the study population at OFAMS baseline visit or during the 
baseline study.  
Variable Values 
Patients, N 80 
Females, N (%) 52 (65) 
Age, mean (SD) 38.3 (8.3) 
Years from diagnosis, mean (SD) 1.9 (3.2) 
EDSS score, mean (SD) 1.9 (0.84) 
Seasonally adjusted 25(OH)D during baseline study, mean (SD) 74.1 (18.1) 
Tobacco users during baseline study, N(%)a 49 (61.3) 
BMI in kg/m2 during baseline study, mean (SD) 25.6 (4.2) 
SD: standard deviation; 25(OH)D: 25-hydroxyvitamin D nmol/L; BMI: body 
mass index. 
a Tobacco users defined as serum cotinine levels > 85 nmol/L in ≥60% of five 
consecutive samples. 
K. Wesnes et al.                                                                                                                                                                                                                                 
Multiple Sclerosis and Related Disorders 50 (2021) 102801
4
and disease status. The association was mainly driven by levels during 
spring when 25(OH)D reached its seasonal nadir. Further, a ceiling ef-
fect in the association appeared around 80 nmol/L, as there were only 
minor changes in disease progression for 25(OH)D increases above this 
level. Tobacco use and BMI were not significantly associated with long- 
term disability in our study. 
Our findings on vitamin D are consistent with previous findings on a 
likely role of vitamin D on disease course in MS. While several studies 
have shown a significant relationship between vitamin D levels and 
inflammatory activity in MS over a few years, few have demonstrated 
any significant association between vitamin D levels and disease 
progression (Smolders et al., 2019). This may be due to shorter 
follow-up time, as use of DMTs delay disability progression and the time 
to secondary progressive MS (Claflin et al., 2018, Brown et al., 2019). A 
recent study found poorer long-term (11 years) cognitive performance in 
the Paced Auditory Serial Addition Test in patients with lower 25(OH)D 
levels at baseline (Cortese et al., 2020), which in part supports our re-
sults. Thus, a longer observational period may be necessary to detect a 
potential effect of vitamin D levels on physical and cognitive disability 
scores. 
In our data, a ceiling effect appeared in the association between 25 
(OH)D and disability progression as there was almost no additional 
Table 2 
The association between mean values of lifestyle factors during the baseline study and the 10-year EDSS progression from last EDSS score in the baseline study.   
Quartile 1 Quartile 2 Quartile 3 Quartile 4  Per 1 SD increasea  
Lifestyle factors  Change in EDSS(95%CI) Change in EDSS(95%CI) Change in EDSS(95%CI) p- 
trend 
Change in EDSS (95%CI) p- 
value 
25(OH)Db        
Patients, N 20 18 21 21    
Median (range), nmol/L 54.9 (36.4- 60.1) 66.9 (60.3- 70.7) 77.5 (71.1- 83.8) 97.6 (84.0- 118.4)    
Model 1c Reference 0.13 (-0.67- 0.93) -0.61 (-1.41- 0.19) -0.78 (-1.59- 0.03) 0.024 -0.45 (-0.75- -0.16) 0.003 
Model 2d Reference 0.29 (-0.53- 1.11) -0.59 (-1.38- 0.21) -0.76 (-1.56- 0.05) 0.022 -0.46 (-0.75- -0.17) 0.002 
Model 3e Reference -0.06 (-0.93- 0.82) -0.86 (-1.72- 0.00) -0.99 (-1.83- -0.15) 0.010 -0.49 (-0.79- -0.20) 0.002 
Cotinineb        
Patients, N 20 19 19 22    
Median (range), nmol/L 0.4 (0.0- 1.2) 123.8 (1.2- 400.8) 738.9 (407.7- 946.6) 1140.6 (980.3- 2443.6)    
Model 1c Reference 0.55 (-0.25- 1.35) 0.30 (-0.51- 1.10) -0.17 (-0.98- 0.64) 0.353 -0.09 (-0.38- 0.20) 0.557 
Model 2d Reference 0.48 (-0.28- 1.24) 0.16 (-0.62- 0.94) -0.11 (-0.88- 0.66) 0.393 -0.07 (-0.34- 0.20) 0.618 
Model 3e Reference 0.34 (-0.45- 1.12) -0.07 (-0.88- 0.75) -0.19 (-0.98- 0.60) 0.296 -0.09 (-0.37- 0.20) 0.538 
BMIb        
Patients, N 22 20 19 19    
Median (range), kg/m2 21.5 (17.7- 22.9) 23.8 (22.9- 25.2) 26.3 (25.3- 28.2) 31.1 (28.8- 38.3)    
Model 1c Reference 0.04 (-0.75- 0.82) -0.10 (-0.90- 0.69) -0.51 (-1.31- 0.28) 0.157 -0.20 (-0.48- 0.08) 0.160 
Model 2d Reference 0.11 (-0.64- 0.86) -0.13 (-0.89- 0.63) -0.43 (-1.19- 0.33) 0.182 -0.20 (-0.47- 0.06) 0.134 
Model 3e Reference 0.02 (-0.74- 0.78) -0.15 (-0.91- 0.62) -0.40 (-1.16- 0.36) 0.247 -0.18 (-0.44- 0.09) 0.189 
SD: standard deviation; CI: confidence interval; 25(OH)D: 25- hydroxyvitamin D; BMI: body mass index. 
a 1 SD for seasonally adjusted 25(OH)D =18.7 nmol/L, 1 SD for mean cotinine= 523.8 nmol/L, 1 SD for mean BMI= 4.2 kg/m2 
b Mean values for the baseline period based on N consecutive samples, where N= 9 for seasonally adjusted 25(OH)D, N=5 for cotinine and N=10 for BMI. 
c Model 1: Adjusted for sex, age and EDSS score at last visit in the baseline study. 
d Model 2: Model 1 + mutually adjusted for 25(OH)D, cotinine and BMI as standardized continuous variables. 
e Model 3: Model 2 + further adjusted for disease duration from year of diagnosis until follow-up (2017), use of disease-modifying treatment at follow-up (none, less 
potent, potent), brain MRI activity (cumulative Combined Unique Activity) and relapse rate during the baseline study. 
Fig. 1. The seasonal fluctuation of 25-hydroxyvitamin D levels based on sample analyses in the baseline study shown by a fitted LOESS curve with 95% confi-
dence intervals. 
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benefit for levels above 80 nmol/L. This finding is in line with a previous 
observational study among 156 RRMS patients on IFN-β or glatiramer 
acetate who were supplemented with vitamin D3. During follow-up, the 
relapse incidence rate significantly decreased until 25(OH)D levels 
reached 110-120 nmol/L - above this, the relapse rate stabilized 
(Pierrot-Deseilligny et al., 2012). Overall, this may suggest that the 
optimal 25(OH)D level for MS patients could lay within a high normal 
range of 80-120 nmol/L. 
In our study population, 25(OH)D levels during spring had the 
strongest association with long-term disability. This may be explained 
by the “vitamin D winter” (Engelsen et al., 2005) period at latitudes 
above 50◦ when UVB radiation, the main natural source of vitamin D 
(Prietl et al., 2013), is too weak to induce any meaningful cutaneous 
synthesis of pre-vitamin D (Engelsen et al., 2005). This lack of synthesis 
cannot be fully compensated by a 15-25 days half-life of 25(OH)D in 
non-supplemented individuals (Martinaityte et al., 2017), making early 
spring extra prone for insufficient levels. Other studies have similarly 
found higher relapse rate during (early) spring (Miclea et al., 2017, 
Spelman et al., 2014). Vitamin D supplementation can compensate for 
the seasonal UVB-related variations in 25(OH)D (Miclea et al., 2017), 
and may also increase the half-life through storage in adipose tissue 
(Martinaityte et al., 2017), thus likely avoiding the lowest levels during 
the winter months at high latitudes. 
The association between vitamin D and MS can be explained through 
plausible biological mechanisms. Both antigen-presenting cells of the 
innate immune system and T- and B-lymphocytes of the adaptive im-
mune system express vitamin D receptors and are able to synthesize the 
active vitamin D compound calcitriol (Prietl et al., 2013, Hart et al., 
2011). Through various mechanisms, calcitriol modulates the immune 
system into a more tolerogenic and anti-inflammatory state, thus likely 
Fig. 2. The association between dichotomized 
seasonal 25-hydroxyvitamin D levels and long- 
term EDSS progression. 
The seasonal 25-hydroxyvitamin D levels are 
dichotomized into “< median” and “≥ median” 
values and further adjusted for sex, age and 
EDSS score at last visit in the baseline study. 
Change in EDSS is the difference between the 
EDSS score at follow-up and the last EDSS score 
in the baseline study. The plots on the right side 
illustrate the estimates. 25(OH)D: 25-hydroxy-
vitamin D; IQR: interquartile range; CI: confi-
dence interval.   
Fig. 3. Seasonally adjusted 25-hydroxyvitamin D levels and the increase in EDSS score fitted by a LOESS curve. 
The increase in EDSS score is defined as the follow-up EDSS score subtracted by the last EDSS score in the baseline study. 
The vertical lines correspond to the fifth, 25th, 50th, 75th, and 95th percentile of serum 25-hydroxyvitamin D levels. 
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preventing and down-scaling autoimmune actions (Prietl et al., 2013). 
On the other hand, UVB radiation itself has likely immunomodulatory 
effects independent of the vitamin D pathway (Hart et al., 2011). 
However, when adjusting for cumulative sun exposure in our models, 
only a minor influence on the estimates was seen, suggesting that our 
results likely represent effects of vitamin D rather than UVB radiation. 
In contrast to other cohorts (Healy et al., 2009, Manouchehrinia 
et al., 2013), we found no significant association between tobacco use 
and EDSS progression. Our results may have been affected by generally 
low disease progression in the population and beneficial effect of 
smoking cessation (Ramanujam et al., 2015) during follow-up (21.3% 
fewer tobacco users at follow-up visit). Since we used a nicotine 
metabolite to classify tobacco use in the baseline study, the results could 
potentially have been influenced by snuff use, which also contains 
nicotine and has been associated with a decreased risk for MS (Hed-
strom et al., 2009). However, only three tobacco users in the baseline 
study reported a history of solely snuff use at follow-up, making it un-
likely that our results can be explained by many snuff-users relative to 
smokers. 
For BMI, we observed a non-significant trend towards less EDSS 
progression with higher BMI. Studies on BMI and long-term outcomes in 
MS may be difficult to interpret, as MS itself or changes in diet and ac-
tivity may affect BMI (Habek et al., 2010), making findings prone to 
reverse causation. Patients with MS tend to have lower mean BMI 
(Nortvedt et al., 2005, Dardiotis et al., 2019), and gain less weight with 
age as compared to the general population (Bove et al., 2016, Wesnes 
et al., 2015), which could suggest that maintaining a higher BMI over 
the years reflects a more benign MS with less chronic disease burden 
affecting weight. This is consistent with other observations in our study, 
as use of potent DMT at follow-up was more prevalent in the lowest BMI 
quartile (54.5%) than in the highest quartile (31.6%). 
Our study has several strengths. First, it benefits from a prospective 
design, a well-defined cohort, and a long follow-up time. Second, the 
lifestyle variables are based on objective and repeated measures over 24 
months, making the results less prone to extreme values in single 
observations. Third, we could adjust for several potential confounders 
and explore the importance of seasonality in the relationship between 25 
(OH)D levels and disability progression. 
There are also some limitations to our study. The relatively small 
sample size may have limited the statistical power to detect associations 
in our study (i.e., increasing the likelihood of a type II error). In addition, 
the low level of disease progression in the study group could have 
influenced our findings, and factors that were not associated with pro-
gression in our study (e.g., smoking and BMI) may be more relevant for 
patients with a more aggressive disease course. Since the baseline study 
and the follow-up study was separated by a long period, we did not have 
detailed information on lifestyle habits between the two studies. It is 
therefore possible that lifestyle changes, such as increasing use of 
vitamin D supplements, may have attenuated the associations. At follow- 
up, only one EDSS score per patient was available, which could have 
been influenced by the patients’ mood and level of fatigue at the time of 
assessment. However, such day-to-day changes may act in both di-
rections, and are therefore less likely to affect the results. Our study 
population was originally recruited for a randomized clinical trial based 
on specific inclusion and exclusion criteria (Torkildsen et al., 2012), and 
may not be fully representative of the general MS population. Still, our 
findings on vitamin D are consistent with previous prospective studies 
and are biologically plausible. Lastly, we cannot exclude the possibility 
that our findings may be affected by residual or unmeasured con-
founding that we could not account for. 
5. Conclusions 
In summary, we found a significant association between higher 
vitamin D levels and lower long-term disability progression in patients 
with MS, suggesting that vitamin D may have a favourable effect on 
long-term outcomes in MS. This association seems to be driven by sea-
sonal low levels during late winter/early spring at latitudes above 50◦. 
No clear association was found between tobacco use or BMI and long- 
term disability scores, indicating that these factors may have less rele-
vance for long-term prognosis. 
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